Concepedia

Publication | Open Access

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

DOIFull Paper Access

54

Citations

20

References

2017

Year

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski, Ivan Staykov, Eva Dokoupilová, Asta Baranauskaitė, Roman Yatsyshyn, Mevludin Mekić, Wieskawa Porawska,
Lara D. Veeken

Abstract

ClinicalTrials.gov (http://clinicaltrials.gov; NCT01936181) and EudraCT (https://www.clinicaltrialsregister.eu; 2012-005733-37).

References

YearCitations

Page 1